Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of DA-302168S tablets in adults with overweight or obesity
CTR20261976Phase 3Active
- Sponsor
- Chengdu Di'ao Pharmaceutical Group
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of DA-302168S in obesity, Overweight, sponsored by Chengdu Di'ao Pharmaceutical Group. Started Jun 2026; status: active.
02
Drugs
DA-302168S
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20261976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261976.